GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Crescent Biopharma Inc (NAS:CBIO) » Definitions » 6-1 Month Momentum %

CBIO (Crescent Biopharma) 6-1 Month Momentum % : N/A% (As of Jul. 23, 2025)


View and export this data going back to 2025. Start your Free Trial

What is Crescent Biopharma 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2025-07-23), Crescent Biopharma's 6-1 Month Momentum % is N/A%.

The industry rank for Crescent Biopharma's 6-1 Month Momentum % or its related term are showing as below:

CBIO's 6-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -10.71
* Ranked among companies with meaningful 6-1 Month Momentum % only.

Competitive Comparison of Crescent Biopharma's 6-1 Month Momentum %

For the Biotechnology subindustry, Crescent Biopharma's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Crescent Biopharma's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crescent Biopharma's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Crescent Biopharma's 6-1 Month Momentum % falls into.


;
;

Crescent Biopharma  (NAS:CBIO) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Crescent Biopharma  (NAS:CBIO) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Crescent Biopharma 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Crescent Biopharma's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Crescent Biopharma Business Description

Traded in Other Exchanges
N/A
Address
221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.